Compare OCUL & LX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCUL | LX |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 666.3M |
| IPO Year | 2014 | 2017 |
| Metric | OCUL | LX |
|---|---|---|
| Price | $14.62 | $3.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 1 |
| Target Price | ★ $22.56 | $3.50 |
| AVG Volume (30 Days) | ★ 3.7M | 2.8M |
| Earning Date | 11-04-2025 | 11-24-2025 |
| Dividend Yield | N/A | ★ 11.90% |
| EPS Growth | N/A | ★ 125.70 |
| EPS | N/A | ★ 1.44 |
| Revenue | $55,783,000.00 | ★ $1,933,903,250.00 |
| Revenue This Year | N/A | $1.87 |
| Revenue Next Year | $14.88 | $10.02 |
| P/E Ratio | ★ N/A | $2.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.79 | $3.15 |
| 52 Week High | $16.44 | $11.64 |
| Indicator | OCUL | LX |
|---|---|---|
| Relative Strength Index (RSI) | 63.98 | 35.40 |
| Support Level | $11.15 | $3.19 |
| Resistance Level | $16.44 | $3.41 |
| Average True Range (ATR) | 0.77 | 0.16 |
| MACD | 0.32 | 0.05 |
| Stochastic Oscillator | 65.72 | 19.18 |
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.